Literature DB >> 24746572

A simulation framework for modeling tumor control probability in breast conserving therapy.

Wei Chen1, Kenneth Gilhuijs2, Joep Stroom3, Harry Bartelink1, Jan-Jakob Sonke4.   

Abstract

BACKGROUND AND
PURPOSE: Microscopic disease (MSD) left after tumorectomy is a major cause of local recurrence in breast conserving therapy (BCT). However, the effect of microscopic disease and RT dose on tumor control probability (TCP) was seldom studied quantitatively. A simulation framework was therefore constructed to explore the relationship between tumor load, radiation dose and TCP.
MATERIALS AND METHODS: First, we modeled total disease load and microscopic spread with a pathology dataset. Then we estimated the remaining disease load after tumorectomy through surgery simulation. The Webb-Nahum TCP model was extended by clonogenic cell fraction to model the risk of local recurrence. The model parameters were estimated by fitting the simulated results to the observations in two clinical trials.
RESULTS: Higher histopathology grade has a strong correlation with larger MSD cell quantity. On average 12.5% of the MSD cells remained in the patient's breast after surgery but varied considerably among patients (0-100%); illustrating the role of radiotherapy. A small clonogenic cell fraction was optimal in our model (one in every 2.7*10(6)cells). The mean radiosensitivity was estimated at 0.067Gy(-1) with standard deviation of 0.022Gy(-1).
CONCLUSION: A relationship between radiation dose and TCP was established in a newly designed simulation framework with detailed disease load, surgery and radiotherapy models.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Breast-conserving therapy; Microscopic disease; Monte-Carlo simulation; Tumor control probability

Mesh:

Year:  2014        PMID: 24746572     DOI: 10.1016/j.radonc.2014.03.004

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  2 in total

Review 1.  Radiation oncology in the era of precision medicine.

Authors:  Michael Baumann; Mechthild Krause; Jens Overgaard; Jürgen Debus; Søren M Bentzen; Juliane Daartz; Christian Richter; Daniel Zips; Thomas Bortfeld
Journal:  Nat Rev Cancer       Date:  2016-03-18       Impact factor: 60.716

2.  Clinical Target Volume: The Third Front.

Authors:  Leonard Kim; Cuihuan Wang; Atif Khan; Mark Pierce
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-02-04       Impact factor: 7.038

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.